Acadia Pharmaceuticals vs TG Therapeutics
ACAD and TGTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACAD and TGTX compare
TG Therapeutics is the larger company, worth 3.0 times as much as Acadia Pharmaceuticals ($9.6B against $3.2B).
On earnings, Acadia Pharmaceuticals is cheaper: it trades at 8.3× trailing earnings, against 22.9× for TG Therapeutics.
TG Therapeutics grew revenue faster over the last twelve months (76.1% versus 11.8% for Acadia Pharmaceuticals).
TG Therapeutics keeps more of each dollar of sales as profit, with a net margin of 55.2% compared with 33.4% at Acadia Pharmaceuticals.
Acadia Pharmaceuticals scores higher on the StockData Score (16 against 9 for TG Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACAD | TGTX |
|---|---|---|
| Size and price | ||
| Market cap | $3.2B | $9.6B |
| Share price | $18.32 | $62.71 |
| Change, 1 year | −23.7% | 102% |
| Change, 5 years | −2.5% | 162% |
| Beta (5Y) | 0.53 | 0.47 |
| Employees | 798 | 399 |
| StockData Score | ||
| Total score | 16 (better) | 9 |
| Valuation score | 4 (better) | 1 |
| Growth score | 2 | 2 |
| Performance score | 4 | 4 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 8.3× (better) | 22.9× |
| P/S | 2.8× (better) | 12.0× |
| P/B | 2.4× (better) | 15.9× |
| EV/EBITDA | 25.5× (better) | 71.3× |
| P/FCF | 21.7× (better) | 552× |
| FCF yield | 4.6% (better) | 0.18% |
| Fair value | $25.26 | $60.66 |
| Margin of safety | 27.5% (better) | −3.4% |
| Growth | ||
| Revenue growth (TTM) | 11.8% | 76.1% (better) |
| Revenue growth, 5Y average | 19.4% | 427% (better) |
| Net income growth (TTM) | 71.3% | 630% (better) |
| EPS growth (TTM) | 66.2% | 641% (better) |
| Profitability | ||
| Gross margin | 91.1% (better) | 82.4% |
| Operating margin | 7.6% | 17.1% (better) |
| Net margin | 33.4% | 55.2% (better) |
| FCF margin | 12.8% (better) | 2.2% |
| Return on equity | 35.7% | 100% (better) |
| Return on invested capital | 42.1% (better) | 27.8% |
| Financial health | ||
| Debt / equity | 0.00 | 1.23 (better) |
| Net debt / EBITDA | – | 0.98 |
| Interest coverage | – | 3.6× |
| Current ratio | 3.39 | 4.27 (better) |
| Altman Z-score | 4.32 | 6.07 (better) |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | −1.5% | 1.9% (better) |
| Shareholder yield | −1.5% | 1.9% (better) |
| Ownership | ||
| Held by institutions | 97.9% | 72.6% |
| Held by insiders | 27.8% | 16.1% |
| Insider net buying, 12 months | −$2.5M | −$275K (better) |
| Short interest, % of float | 6.7% | 22.4% |
Go deeper
- ACAD stock overview
- ACAD income statement
- ACAD valuation and score
- TGTX stock overview
- TGTX income statement
- TGTX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.